Compare VRAR & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VRAR | NCNA |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.2M | 13.8M |
| IPO Year | 2021 | 2017 |
| Metric | VRAR | NCNA |
|---|---|---|
| Price | $1.19 | $3.25 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $2.62 | N/A |
| AVG Volume (30 Days) | ★ 172.5K | 83.3K |
| Earning Date | 02-12-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $9,488,209.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $72.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.60 | N/A |
| 52 Week Low | $0.77 | $2.78 |
| 52 Week High | $2.05 | $268.00 |
| Indicator | VRAR | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 59.98 | 41.26 |
| Support Level | $1.03 | $3.14 |
| Resistance Level | $1.17 | $3.35 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.08 | 17.91 |
The Glimpse Group Inc is a diversified immersive technology platform company, focused on providing enterprise solutions in virtual reality (VR), augmented reality (AR), and spatial computing. The company operates multiple subsidiaries that develop VR and AR software and services across various industries, including corporate training, education, healthcare, government, defense, marketing, retail, and financial services. It also offers AI-driven spatial computing platforms that support simulations, social VR, behavioral health, and corporate events. The Company reports its revenues in three categories: Software Services, Software License and Software-as-a-Service (SaaS), and Royalty Income, with the majority being from the Software Services category.
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.